



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/568,488	03/25/2008	Brett P. Monia	ISIS.03/PCT-US	7913
25871 7590 06/30/2008 SWANSON & BRATSCHEUN, L.L.C. 8210 SOUTHPARK TERRACE LITTLETON, CO 80120				
EXAMINER				
GIBBS, TERRA C				
ART UNIT		PAPER NUMBER		
1635				
MAIL DATE		DELIVERY MODE		
06/30/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/568,488

Applicant(s)

MONIA ET AL.

Examiner

TERRA C. GIBBS

Art Unit

1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on February 14, 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1, 8-10, 14-20, 25, 29, 31, 34, 41-43, 47-53 and 58 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) See Continuation Sheet are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

Continuation of Disposition of Claims: Claims subject to restriction and/or election requirement are 1,8-10,14-20,25,29,31,34,41-43,47-53 and 58.

DETAILED ACTION

This Office Action is a response to Applicant's Preliminary Amendment filed February 14, 2006.

Claims 2-7, 11-13, 21-24, 26-28, 30, 32, 33, 35-40, 44-46, 54-57, and 59-67 have been canceled. Claims 1, 10, 29, 31, 34, and 43 have been amended.

Claims 1, 8-10, 14-20, 25, 29, 31, 34, 41-43, 47-53, and 58 are pending in the instant application.

Claims 1, 8-10, 14-20, 25, 29, 31, 34, 41-43, 47-53, and 58 are subject to restriction as detailed below:

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

Group I. Claims 1, 8-10, 14-20, 25, 29, and 31, drawn to a method for decreasing airway hyperresponsiveness or airway inflammation in an animal, comprising administering to said animal, an antisense compound 13 to 30 nucleobases in length, wherein the antisense compound is targeted to a nucleic acid molecule encoding a p38 α mitogen-activated protein kinase, classifiable in class 514, subclass 44, for example. **If this Group is elected, a further restriction is required as detailed below.**

Group II. Claims 34, 41-43, 47-53, and 58, drawn to an antisense compound 13 to 30 nucleobases in length targeted to a nucleic acid molecule encoding a p38 α mitogen-activated protein kinase, classifiable in class 536,

subclass 24.5, for example. **If this Group is elected, a further restriction is required as detailed below.**

The inventions are distinct, each from the other, because of the following reasons:

Group II is related to Group I as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the antisense compound 13 to 30 nucleobases in length targeted to a nucleic acid molecule encoding a p38 α mitogen-activated protein kinase of Group II can be used in a materially different process such as a hybridization probe in a method of identifying p38 α mitogen-activated protein kinase gene expression *in situ*, which is a materially different process than the method for decreasing airway hyperresponsiveness or airway inflammation in an animal, comprising administering to said animal, an antisense compound 13 to 30 nucleobases in length, wherein the antisense compound is targeted to a nucleic acid molecule encoding a p38 α mitogen-activated protein kinase of Group I. Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the Examiner if restriction were not required because the inventions require a different field of search (see MPEP 808.02), restriction for examination purposes as indicated is proper.

Art Unit: 1635

Upon election of Group I or Group II, claims 1 and 34, respectively, are subject to an additional restriction since they are not considered to be a proper genus/Markush. See MPEP 803.02 - PRACTICE RE MARKUSH-TYPE CLAIMS

- If the members of the Markush group are sufficiently few in number or so closely related that a search and examination of the entire claim can be made without serious burden, the examiner must examine all the members of the Markush group in the claim on the merits, even though they are directed to independent and distinct inventions. In such a case, the examiner will not follow the procedure described below and will not require restriction. Since the decisions in *In re Weber*, 580 F.2d 455, 198 USPQ 328 (CCPA 1978) and *In re Haas*, 580 F.2d 461, 198 USPQ 334 (CCPA 1978), it is improper for the Office to refuse to examine that which applicants regard as their invention, unless the subject matter in a claim lacks unity of invention. In *re Harnish*, 631 F.2d 716, 206 USPQ 300 (CCPA 1980); and *Ex parte Hozumi*, 3 USPQ2d 1059 (Bd. Pat. App. & Int. 1984). Broadly, unity of invention exists where compounds included within a Markush group (1) share a common utility, and (2) share a substantial structural feature disclosed as being essential to that utility.

Both Groups I and II specifically claims an antisense compound 13 to 30 nucleobases in length targeted to a nucleic acid molecule encoding a p38 α mitogen-activated protein kinase, wherein the antisense compound is targeted to nucleotides 562 to 648; 659 to 688; or 1194 to 1277 of SEQ ID NO:1 or nucleotides 3722 to 3747 of SEQ ID NO:127 or methods of using said antisense compound for decreasing airway hyperresponsiveness or airway inflammation in

Art Unit: 1635

an animal. Although the antisense compounds and methods of using said antisense compounds claimed each comprise antisense compounds targeted to a nucleic acid molecule encoding a p38 α mitogen-activated protein kinase, the instant antisense compounds are considered to be unrelated, since each antisense compound is structurally and functionally independent and distinct for the following reasons: each antisense compound has a unique nucleotide sequence (as per Applicant's disclosure at Tables 1, 15, and 21) and each antisense compound, upon binding to a nucleic acid molecule encoding a p38 α mitogen-activated protein kinase, regulates the gene to a different degree (as per Applicant's disclosure at Tables 16 and 28-30). As such the Markush/genus of antisense compounds and methods of using said antisense compounds claimed in Groups I and II are not considered to constitute a proper genus, and is therefore subject to restriction. Furthermore, a search of more than one (1) of the antisense compounds and methods of using said antisense compounds as claimed in Groups I and II presents an undue burden on the Patent and Trademark Office due to the complex nature of the search and corresponding examination of more than one (1) of the claimed antisense compounds and methods of using said antisense compounds. In view of the foregoing, one (1) antisense compound or one (1) method of using said antisense compound is considered to be a reasonable number of sequences for examination. Accordingly, if Applicants elect Group I, Applicants are required to elect a method of using one (1) antisense compound as recited in claim 1. That is, Applicants are required to elect one antisense compound targeted to either nucleotides 562

Art Unit: 1635

to 648 of SEQ ID NO:1; nucleotides 659 to 688 of SEQ ID NO:1; nucleotides 1194 to 1277 of SEQ ID NO:1; or nucleotides 3722 to 3747 of SEQ ID NO:127 from claim 1. If Applicants elect Group II, Applicants are required to one (1) antisense compound as recited in claim 34. That is, Applicants are required to elect one antisense compound targeted to either nucleotides 562 to 648 of SEQ ID NO:1; nucleotides 659 to 688 of SEQ ID NO:1; nucleotides 1194 to 1277 of SEQ ID NO:1; or nucleotides 3722 to 3747 of SEQ ID NO:127 from claim 34. Note that this is not a species election but a restriction of distinct and independent inventions: unique and structurally distinct nucleotide sequences.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper. Also, because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the Examiner if restriction were not required because the inventions require a different field of search (see MPEP 808.02), restriction for examination purposes as indicated is proper.

Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above and there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:

- (a) the inventions have acquired a separate status in the art in view of their different classification;
- (b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;
- (c) the inventions require a different field of search (for example, searching

Art Unit: 1635

different classes/subclasses or electronic resources, or employing different search queries);

(d) the prior art applicable to one invention would not likely be applicable to another invention;

(e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of an invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(l).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the

Art Unit: 1635

rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Terra C. Gibbs whose telephone number is 571-272-0758. The examiner can normally be reached on 9 am - 5 pm M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James "Doug" Schultz can be reached on 571-272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-

Art Unit: 1635

free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

February 8, 2008

/Terra Cotta Gibbs/

Application Number**Application/Control No.**

10/568,488

**Applicant(s)/Patent under
Reexamination**

MONIA ET AL.

Examiner

TERRA C. GIBBS

Art Unit

1635